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Podoplanin (PDPN) is a well-conserved, mucin-type transmembrane protein expressed in
multiple tissues during ontogeny and in adult animals, including the brain, heart, kidney,
lungs, osteoblasts, and lymphoid organs. Studies of PDPN-deﬁcient mice have demon-
strated that this molecule plays a critical role in development of the heart, lungs, and
lymphatic system. PDPN is widely used as a marker for lymphatic endothelial cells and
ﬁbroblastic reticular cells of lymphoid organs and for lymphatics in the skin and tumor
microenvironment. Much of the mechanistic insight into PDPN biology has been gleaned
from studies of tumor cells; tumor cells often upregulate PDPN as they undergo epithelial-
mesenchymal transition and this upregulation is correlated with increased motility and
metastasis.The physiological role of PDPN that has been most studied is its ability to aggre-
gate and activate CLEC-2-expressing platelets, as PDPN is the only known endogenous
ligand for CLEC-2. However, more recent studies have revealed that PDPN also plays crucial
roles in the biology of immune cells, includingT cells and dendritic cells.This review will pro-
vide a comprehensive overview of the diverse roles of PDPN in development, immunology,
and cancer.
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INTRODUCTION
Podoplanin (PDPN) is a 36- to 43-kDa mucin-type transmem-
brane protein. It has homologues in humans, mice, rats, dogs, and
hamsters and is relatively well conserved between species. PDPN
has awide variety of functions including regulation of organdevel-
opment, cell motility, and tumorigenesis and metastasis (Wicki
and Christofori, 2007; Suzuki-Inoue et al., 2011). PDPN has been
identiﬁed and studied in many different contexts; thus, it has
been given several names. PDPN was ﬁrst described on lymphatic
endothelial cells (LECs) as theE11 antigen (Wetterwald et al.,1996)
and on ﬁbroblastic reticular cells (FRCs) of lymphoid organs and
thymic epithelial cells as gp38 (Farr et al., 1992a,b; Table 1). PDPN
is alsohomologous toT1a/rTI40, oneof theﬁrstmolecularmarkers
of alveolar type I epithelial cells (Rishi et al., 1995; Williams et al.,
1996; Table 1), PA2.26, which is upregulated in skin keratinocytes
upon injury (Scholl et al., 1999), OTS-8, a molecule induced in
osteoblasts upon phorbol ester treatment (Nose et al., 1990), and
Aggrus, a platelet-aggregating factor (Kato et al., 2003). Finally, this
molecule was given the name podoplanin due to its expression on
kidney podocytes and possible involvement in the ﬂattening of
podocyte foot processes (Breiteneder-Geleff et al., 1997).
While PDPN expression patterns in many of these cells have
been well characterized, there is still little known about the physi-
ological functions of this protein. PDPN has been reported to bind
to the C-type lectin receptor CLEC-2, which is highly expressed
by platelets and immune cells. However, this interaction has only
been extensively studied with regard to platelets. Engagement of
PDPN by CLEC-2 on platelets leads to platelet aggregation and
activation, and this process is critical for the maintenance of nor-
mal lymphatic vessels (Bertozzi et al., 2010; Suzuki-Inoue et al.,
2010). PDPN has also been used as a marker for FRCs in the lymph
node (LN) and spleen, but there is limited data on whether PDPN
expression is required for the function of these cells or inﬂuences
their interactions with leukocytes.
The majority of data examining the function and signaling
pathways of PDPN are from studies of PDPN overexpression
in tumor cells. While these studies certainly provide critical
insight into cellular and molecular aspects of PDPN biology, it
is important to understand whether PDPN functions similarly in
non-pathological settings and in cell types where it is naturally
expressed. Here, we will review what is currently known about
the structure, molecular interactions, and in vivo roles of PDPN.
We will focus on the function of PDPN on stromal cells, includ-
ing epithelial cells, endothelial cells, and ﬁbroblasts but will also
describe recent studies of PDPN expression by immune cells.
PDPN IN DEVELOPMENT
Podoplanin is ﬁrst expressed in the developing mouse embryo
on day E9 in the foregut, proepicardial organ, and central ner-
vous system (CNS; Williams et al., 1996; Mahtab et al., 2009;
Table 1). Throughout development, it is also expressed in the fetal
rat kidney, choroid plexus, intestine, and esophagus (Williams
et al., 1996; Table 1). Over time, PDPN expression is increasingly
restricted such that in an adult animal, PDPN is predominantly
www.frontiersin.org September 2012 | Volume 3 | Article 283 | 1
“ﬁmmu-03-00283” — 2012/9/12 — 10:33 — page 2 — #2
Astarita et al. PDPN in development, immune system, and cancer
Table 1 | Podoplanin expression and function in organs and immune cells.
Organ Time of expression PDPN function Reference
Central nervous
system
Beginning day E9, becomes restricted to choroid
plexus in adult mouse
No speciﬁc function reported during development;
high PDPN expression in brain tumors
Williams et al. (1996),
Kaji et al. (2012),
Peterziel et al. (2012)
Heart Expressed in entire organ on day E9; continued
expression in adult heart
Required for normal heart development,
speciﬁcally for EMT in epicardium-derived cells
Martín-Villar et al. (2005),
Mahtab et al. (2008, 2009),
Douglas et al. (2009)
Lungs Appears in foregut on day E9 before lung buds;
subsequently restricted to alveolar type I
epithelial cells
Required for lung development; speciﬁcally the
effective maturation of alveolar type I epithelial
cells
Ramirez et al. (2003)
Intestine Expressed on day E9 in foregut; continued
expression in lamina propia
No speciﬁc function determined Farr et al. (1992a),
Williams et al. (1996)
Lymphoid organs Present in spleen 4 days postnatally; in adult,
expression by FRCs, LECs, and FDCs in lymph
node and spleen, and thymic medullary epithelial
cells
Required for proper formation and organization of
lymph nodes and spleen; necessary for efﬁcient
DC migration to and within lymph nodes; highly
expressed by stroma and someT cells in ectopic
lymphoid tissue
Farr et al. (1992a),
Bekiaris et al. (2007),
Raica et al. (2010),
Peters et al. (2011),
Acton et al. (2012),
Yu et al. (2007)
Immune cell Expression pattern Function Reference
T cell Expressed only onTH17 cells, not other subsets Plays a role in TH17-driven development of ectopic
germinal centers in EAE
Peters et al. (2011)
Macrophages Expressed by inﬂammatory macrophages, such
as thioglycollate-elicited peritoneal macrophages
Possibly plays a role in response to fungal
infections; can activate platelet aggregation
Hou et al. (2010),
Kerrigan et al. (2012)
expressed in alveolar type I cells, mature osteoblasts, LECs, and
FRCs in the T cell zone of lymphoid organs (Wetterwald et al.,
1996; Williams et al., 1996; Schacht et al., 2003; Table 1). PDPN
is critical for normal development of some of these organs and
has been well studied in PDPN-deﬁcient animals. Pdpn−/− mice
develop normally until around day E10, which coincides with the
appearance of PDPN protein. From days E10–16, approximately
40% of Pdpn−/− embryos die; the ones that survive to birth die
within a few days (Mahtab et al., 2008). However, interestingly,
when themice are crossed onto aC57Bl/6 background,manymore
embryos survive to birth, and although 50% die in the ﬁrst week,
approximately 20% of the mice do survive to adulthood (Uhrin
et al., 2010). The reason why the genetic background affects the
severity of the defects suffered by the Pdpn−/− mice is intriguing
and warrants further study. Furthermore, it would be of great use
to the ﬁeld to have a conditional knockout of PDPN to avoid these
survival defects.
The defect in blood-lymphatic vascular separation is the phe-
notype most extensively studied in PDPN-deﬁcient mice. On
day E11.5, PDPN ﬁrst appears in the developing circulatory sys-
tem on Prox-1+ lymphatic cells (Schacht et al., 2003). It was
ﬁrst reported by Schacht et al. (2003) that Pdpn−/− mice have
abnormal lymphatic vessels that cannot properly regulate lymph
ﬂow and that this defect did not appear in blood vessels. These
ﬁndings were further supported by Fu et al. (2008), who reported
that endothelial cell expression of PDPN was responsible for a
blood-lymphatic misconnection. Furthermore, continued expres-
sion of PDPN into adulthood was required to maintain proper
vascular architecture, as an inducible deletion of T-synthase, a
major glycosyltransferase required for O-glycan synthesis and
normal levels of PDPN expression, showed similar blood-lymph
mixing (Fu et al., 2008).
This non-separation phenotype is also observed in mice where
hematopoietic cells lack Syk, SLP-76, PLCγ2, and CLEC-2
(Abtahian et al., 2003; Sebzda et al., 2006; Suzuki-Inoue et al.,
2010).While platelets and neutrophils both express CLEC-2, it was
initially believed that platelets could not be involved in this pheno-
typebecausemice lackingnearly all platelets hadnormal lymphatic
vasculature (Shivdasani et al., 1995). However, elegant recent stud-
ies have proven that CLEC-2 expression and downstream signaling
through SLP-76 are required speciﬁcally in platelets (Bertozzi et al.,
2010; Osada et al., 2012). The interaction of platelet CLEC-2
and PDPN on LECs induces platelet aggregation and prevents
blood from ﬂowing into new lymphatic vessels budding from the
cardinal vein. Furthermore, injecting a PDPN-blocking antibody
or otherwise inhibiting platelet aggregation is sufﬁcient to dis-
rupt lymphatic development (Uhrin et al., 2010). Overall, the
model that has emerged indicates that during the budding of the
Frontiers in Immunology | Antigen Presenting Cell Biology September 2012 | Volume 3 | Article 283 | 2
“ﬁmmu-03-00283” — 2012/9/12 — 10:33 — page 3 — #3
Astarita et al. PDPN in development, immune system, and cancer
lymph sac from the cardinal vein, PDPN becomes upregulated
on Prox-1+Lyve-1+ LECs and binds with CLEC-2 on platelets.
This interaction activates downstream signaling in platelets, which
results in platelet aggregation. This aggregation then allows for a
complete separation of the budding lymphatic vessels from the
developing blood vessels.
In addition to its role in lymphatic vessel development, PDPN
may play a role in the development or maintenance of lymphoid
organ architecture. In the spleens of mice lacking lymphocytes,
no PDPN expression is observed, although FRCs are still present
as indicated by VCAM-1 and ER-TR7 staining (Ngo et al., 2001;
Bekiaris et al., 2007). It appears that this lack of expression is due
to a lack of lymphotoxin, but it remains unclear exactly which cell
typeprovides that signal duringdevelopment of the spleen. Amore
striking phenotype has been observed by Peters et al. (2011) in that
Pdpn−/− mice lack nearly all LNs, and the ones that develop are
extremely disorganized. The spleens of these mice were present,
but were also disorganized. It is interesting to speculate whether
this phenotype indicates an important function forPDPNonFRCs
and T cells; however, it is also possible that the lack of LNs is due to
impaired lymph ﬂow caused by the malformed lymphatic vessels.
Thus, further work is needed to dissect this phenotype.
The ﬁrst defects described in Pdpn−/− mice were in the lung
(Table 1), as these mice die shortly after birth due to an inability
to inﬂate the lungs (Ramirez et al., 2003). This defect stems from
an impairment in the development of alveolar type I cells. These
cells cover the majority of the lung surface and play a key role in
the proper development of the alveoli, which are the major gas
exchange centers of the lung (Williams, 2003). In normal lung
development, alveolar type I cells exhibit a high proliferation rate
during early and mid-gestation periods, but this high growth rate
slows a few days before birth (Ramirez et al., 2003). However, when
alveolar type I cells lack PDPN, they continue proliferating in later
stages of embryonic development, which is partially explained
by a decrease in the negative cell cycle regulator, p21, at birth
(Millien et al., 2006).
Podoplanin is also necessary for proper development of the
heart (Table 1). PDPN is ﬁrst expressed in the proepicardial organ
on day E9.5 and by day E12.5, it is expressed in most of the
heart. Without PDPN expression, the hearts of developing mice
exhibit hypoplasia in the pulmonary vein, left atrium dorsal wall,
and the atrial septum (Douglas et al., 2009). In this setting, the
lack of PDPN leads to a dysregulation of epithelial-mesenchymal
transition (EMT), a process that involves the transition of sessile
epithelial cells into more motile mesenchymal cells through the
downregulation of epithelial markers, such as adhesion molecules
like E-cadherin (Thiery, 2002). In PDPN-deﬁcient mice, the
epicardium-derived cells responsible for cardiac development
show increased levels of E-cadherin and decreased levels of RhoA
compared with their WT counterparts, which is indicative of
impaired EMT (Mahtab et al., 2008, 2009). While PDPN has been
shown to play a role in regulating EMT (Martín-Villar et al., 2006),
these studies are the ﬁrst evidence that PDPN may play a role in
physiological instances of EMT in non-transformed cells.
Overall, PDPN is crucial for the development of multiple
organs, including the lymphatic system, lungs, and heart. Inter-
estingly, PDPN serves diverse functions in these organs. In some
instances it is required forCLEC-2-dependent platelet aggregation,
but in others it seems to have an intrinsic effect on proliferation
or differentiation in a speciﬁc cell type. This raises the question of
whether PDPN function could to some degree be tissue speciﬁc.
The range of physiological effects downstream of PDPN expres-
sion may be due to different protein interactions and binding
partners in diverse cell types.
MOLECULAR INTERACTIONS AND SIGNALING OF PDPN
Podoplanin contains a single transmembrane domain, a short,
nine amino acid cytoplasmic tail, and a heavily glycosylated extra-
cellular domain (Martín-Villar et al., 2005). While there are no
obvious conserved protein domains in PDPN, several studies have
identiﬁed speciﬁc residues on PDPN that mediate interactions
with other proteins (Figure 1). The ﬁrst hints at the cellular func-
tion of PDPN came from Scholl et al. (1999), who discovered that
PDPN was upregulated in keratinocytes from induced epidermal
carcinogenesis and was localized to membrane protrusions such as
ﬁlopodia and lamellipodia. PDPN co-localized with ezrin, radixin,
and moesin (ERM) family proteins, and was later found to directly
bind ezrin andmoesin. This interaction requires a conservedmotif
of three basic residues in the cytoplasmic tail (see Figure 1) and
overexpression of PDPN resulted in increased phosphorylation
of ERM proteins (Martín-Villar et al., 2006; Wicki et al., 2006).
The ERM proteins function as connectors between integral mem-
brane proteins and the actin cytoskeleton. Phosphorylation causes
a conformational change that exposes binding sites for actin and
other proteins (Fehon et al., 2010). Thus, this interaction likely
underlies many of the effects that PDPN has on cytoskeleton. A
closer examination of the effects of PDPN upregulation revealed
that overexpression of PDPN in epithelial cell lines caused them to
become more mesenchymal in appearance, with decreased stress
ﬁbers and increased ﬁlopodia (Martín-Villar et al., 2006; Wicki
et al., 2006). These changes, in addition to a downregulation of
E-cadherin and other epithelial markers, are indicative of cells
undergoing EMT, which is indeed what Martín-Villar et al. (2006)
observed. However, Wicki et al. (2006) demonstrated that while
PDPN overexpression resulted in increased motility, it did not
result in an E-cadherin switch or EMT. Discrepancies were also
found when the involvement of Rho family small G proteins was
examined. Martín-Villar et al. (2006) reported that PDPN overex-
pression resulted in an increase in RhoA and no change in Rac-1
or Cdc42, while Wicki et al. (2006) found a downregulation in
RhoA, Rac-1, and Cdc42. In addition, Navarro et al. (2010) found
that knocking down PDPN in LECs resulted in decreased levels of
activated RhoA and increased levels in Cdc42. While it is clear that
the expression of PDPN has an effect on the activity levels of these
proteins, more work must be done to fully elucidate the mecha-
nism. As described above, it is possible that PDPN exerts different
effects and utilizes distinct signaling cascades in various cell types,
which could partially explain the observed discrepancies.
Recently, it was discovered that PDPNresides in lipid rafts in the
plasma membrane. Barth et al. (2010) found that PDPN resides
in detergent-insoluble fractions of alveolar type I epithelial cells,
but its function within these rafts remains unknown. It was sub-
sequently reported that human PDPN expressed in Madin–Darby
Canine Kidney (MDCK) type II cells is localized to lipid rafts
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FIGURE 1 | Molecular interactions of PDPN. PDPN interacts with a variety
of intracellular and transmembrane proteins to mediate effects on cell
migration and adhesion. The binding of PDPN to CD44 or ERMs results in
increased cell migration and rearrangement of the actin cytoskeleton to
generate actin-rich protrusions of the membrane. The three amino acids
colored in pink (K, K, R) are the basic residues requires for ERM protein
binding. Interactions between PDPN and CD9 affect metastasis and platelet
aggregation. The engagement of PDPN by CLEC-2 causes increased motility
in DCs and aggregation and activation of platelets. PDPN binds with high
afﬁnity to the chemokine CCL21 and while the consequences of this effect
have not been examined, it may play a role in facilitating leukocyte migration.
Finally, PDPN binding to galectin-8 may modulate adhesion of LECs.
(Fernández-Muñoz et al., 2011). In these cells, the transmembrane
and cytoplasmic domains of PDPN were necessary for association
with lipid rafts. Furthermore, manipulation of this localization
by substituting the transmembrane domain with that of other
proteins inhibited PDPN-mediated increases in EMT, migration,
and phosphorylation of ERMs (Fernández-Muñoz et al., 2011).
Interestingly, cytoskeletal interactions are not required for PDPN
to get into lipid rafts (Barth et al., 2010); however, the cytosolic
domain is necessary (Fernández-Muñoz et al., 2011) and one way
this might be explained is via interactions with ERMs, given that
ezrin is also raft-associated.
Given that the cytoplasmic tail of PDPN is extremely short, it is
difﬁcult to imagine that there ismuch direct signaling downstream
of PDPN other than through the ERM proteins, simply due to
spatial restrictions. Interestingly, however, PDPN also interacts
with two integral membrane proteins that could help to further
explain how it affects cell motility and metastasis. CD44, which is
widely expressed, affectsmany cellular functions such asmigration
and adhesion, and the expression of some isoforms is linked to
more invasive cancers. Martín-Villar et al. (2010) noted that CD44
and PDPN were coordinately upregulated in aggressive cancer
cell lines and subsequently found that they directly bind to one
another. This interaction is dependent on correct glycosylation
of the extracellular domain of PDPN, and CD44 expression is
required for PDPN-induced cell migration (Martín-Villar et al.,
2010). Additionally, Nakazawa et al. (2008) found that PDPN
directly interacts with the tetraspanin CD9 through transmem-
brane domains 1 and 2 of CD9. CD9 acts as a tumor suppressor
in many cancers (Zöller, 2009), and co-expression of CD9 and
PDPN resulted in a CD9-mediated decrease of PDPN-induced
metastasis. CD9 also inhibited PDPN-mediated platelet aggrega-
tion without directly interfering with CLEC-2 binding of PDPN
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(Nakazawa et al., 2008). This ﬁnding indicates thatCD9potentially
disrupts CLEC-2 multimerization, which is required for down-
streamsignaling. These interactionsprovide some insight intohow
PDPN can exert striking effects on actin cytoskeleton rearrange-
ment, cell motility, and metastasis. Still however, much remains
to be elucidated such as the downstream signaling changes that
occur upon PDPN binding to CD9 or CD44, how PDPN over-
expression results in an increase of ERM phosphorylation, and
how that in turn modulates the activity of the Rho family small
G proteins.
The only known receptor for PDPN is CLEC-2, a C-type
lectin that is expressed by platelets, neutrophils, and dendritic
cells (DCs) (Colonna et al., 2000; Sobanov et al., 2001; Kerrigan
et al., 2009; Acton et al., 2012). Glycosylation of T34 on PDPN is
required for CLEC-2 binding of PDPN. This amino acid resides
in the platelet-aggregation stimulating (PLAG) domain, which
is highly conserved between PDPN homologues (Kaneko et al.,
2006). The effect of CLEC-2 engagement by PDPNhas been exten-
sively studied in platelets; however, the effect of this interaction in
PDPN-expressing cells has not been addressed. This is an area that
warrants further exploration, given that in vivo, many PDPN+
cells will be exposed to CLEC-2 signals, whether they are tumor
cells interacting with CLEC-2+ platelets or FRCs interacting with
CLEC-2+ DCs.
Lymphatic endothelial cells and FRCs, the two major subsets
of lymphoid stromal cells, express high levels of PDPN (Malho-
tra et al., 2012; Table 1), but only a few studies have examined
the molecular function of PDPN in these cells. PDPN interacts
with galectin-8 on LECs, and this interaction is also dependent
on PDPN glycosylation (Cueni and Detmar, 2009). Galectin-8
can have varying effects on adhesion depending on whether it
is secreted or membrane-bound (Zick et al., 2004); it seems that
PDPN binding to galectin-8 may affect LEC adhesion, but addi-
tional studies are needed to fully elucidate the consequences of
this interaction. PDPN also binds CCL21 with high afﬁnity, and
this interaction is also dependent on glycosylation of PDPN (Ker-
jaschki et al., 2004). This interaction has interesting implications
for lymphocyte trafﬁcking, as both LECs and FRCs express CCL21
to direct lymphocyte and DC trafﬁcking to the T zone of LNs
(Luther et al., 2000; Bajénoff et al., 2006; Turley et al., 2010).
It has yet to be examined whether the above binding partners
of PDPN are cell-type speciﬁc or how interaction with one pro-
tein affects the binding of PDPN to another interacting molecule.
With the exception of the ERMs and CD44, it remains unclear
whether PDPN can bind to several of these proteins at one time
or whether such interactions might be mutually exclusive. A more
global understanding of these various interactions is critical to
our overall understanding of PDPN’s molecular functions and
downstream signaling.
TRANSCRIPTIONAL CONTROL OF PDPN EXPRESSION
Information about the transcriptional control of PDPN ﬁrst came
from the early studies of the role of PDPN in the development
of the lymphatic system. The fact that PDPN was speciﬁcally
expressed on differentiating LECs but not nearby BECs led to
the discovery that Prox-1, the major regulator of LEC differen-
tiation, controlled the induction of PDPN (Hong et al., 2002).
In fact, forced expression of Prox-1 was sufﬁcient to induce a
LEC-like phenotype in differentiated BECs, including the upreg-
ulation of PDPN (Hong et al., 2002). Furthermore, it was later
found that IL-3, which is involved controlling the differentia-
tion of a variety of hematopoietic cells and is produced by LECs
but not BECs, was capable of upregulating Prox-1 and PDPN
(Gröger et al., 2004). However, Prox-1 is not expressed in FRCs
or in many of the other cells types expressing PDPN. Therefore
alternative pathways must be involved in PDPN expression in tis-
sues other than lymphatics. This may be another reason why the
physiological functions of PDPN are so varied between different
systems.
In skin cancers, osteosarcomas, and gliomas, PDPN is regu-
lated by the AP-1 transcription factor (Durchdewald et al., 2008;
Kunita et al., 2011; Peterziel et al., 2012). AP-1 is a heterodimeric
complex comprised of Fos and Jun proteins. Both Fos and Jun
are critical for progression of many carcinomas, including mod-
els of skin carcinogenesis (Eferl and Wagner, 2003). Durchdewald
et al. (2008) compared genetic proﬁles of skin tumors from mice
that had either WT Fos expression or Fos speciﬁcally deleted in
keratinocytes and found that PDPN was one of the most highly
upregulated genes in the Fos-sufﬁcient samples. Furthermore, they
demonstrated that Fos directly binds to the PDPN promoter. This
interaction was further characterized in gliomas, and it was found
that PTEN expression, a negative regulator of the PI3K-AKT-AP-1
pathway,was inversely correlatedwith PDPNexpression (Figure 2;
Peterziel et al., 2012). Furthermore, the PDPN promoter is heavily
methylated, which keeps it repressed (Peterziel et al., 2012). Thus,
it appears that a major pathway of PDPN upregulation in malig-
nant conditions depends on the activity of Fos and Jun (AP-1)
transcription factors.
Finally, there have been two reports of pro-inﬂammatory
cytokines resulting in PDPN upregulation in disease. In rheuma-
toid arthritis (RA), ﬁbroblast-like synoviocytes are the main
mediators of inﬂammation and tissue destruction and undergo
a process resembling EMT during RA progression (Huber et al.,
2006). Ekwall et al. (2011) recently reported that while PDPN
is absent from the synovium of healthy subjects and patients
with osteoarthritis, it is highly upregulated in RA patients.
Furthermore, expression of PDPN in cultured synoviocytes is
increased upon treatment with IL-1β, TNF-α, or TGF-β1 (Ekwall
et al., 2011). Similarly, PDPN upregulation was observed in ker-
atinocytes treated in vitro with TGF-β, IL-6, IL-22, or IFN-γ
(Honma et al., 2012). The TGF-β-mediated PDPN upregulation
required Smad2/3 and 4 signaling, while STAT1 and STAT3 were
necessary for IFN-γ signaling and STAT1 was required for IL-6
and IL-22 signaling (Honma et al., 2012).
Overall, it appears that a multitude of stimuli can drive PDPN
expression, including normal differentiation factors such as Prox-1
and potentially malignant factors such as pro-tumorigenic signal-
ing pathways and pro-inﬂammatory cytokines. It is possible that
the different pathways controlling PDPNupregulation could result
in the activation of distinct downstream signaling pathways and
therefore different cellular outcomes. For instance, a tumor cell
and a LEC compose two distinct environments with different sig-
naling pathways andmolecules active; upregulating PDPN in these
distinct signaling milieus would likely have diverse outcomes.
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FIGURE 2 |Transcriptional regulation of PDPN expression. PDPN
expression can be upregulated by a number of pro-inﬂammatory cytokines,
including IL-22, IL-6, IFN-γ, TGF-β, IL-1β, andTNF-α, but the signaling
pathways involved are largely unknown. PDPN upregulation induced
byTGF-β requires Smad2/3 and 4 activity, while upregulation induced
by IFN-ψ depends on STAT1 and STAT3 and that of IL-6 and IL-22
depends on STAT3. The PI3K-AKT-AP-1 pathway can also induce
PDPN expression in brain tumors that have lost the negative regulation
normally provided by PTEN. AP-1, a transcription factor comprised of
Fos and Jun proteins, binds to the tetradecanoylphorbol acetate-responsive
element (TRE) in the promoter of PDPN, which is heavily
methylated.
PDPN FUNCTIONS IN THE IMMUNE SYSTEM
While PDPN is a well-established marker for LECs (Wetterwald
et al., 1996), FRCs (Farr et al., 1992b), and follicular dendritic cells
(FDCs) (Yu et al., 2007) of lymphoid organs, until very recently, no
particular function had been ascribed to PDPN in these immune
cell populations. Recently, a PDPN-cre mouse was generated,
which will be a useful tool in targeting PDPN-expressing stro-
mal cells (Onder et al., 2011). Our lab recently demonstrated that
PDPN on FRCs and LECs interacts with CLEC-2 on DCs to pro-
mote DC motility from peripheral sites to LNs and within the T
cell zone (Acton et al., 2012). We found that murine DCs expressed
CLEC-2 and that their migration to draining LNs was impaired
when CLEC-2 was deleted. Conversely, siRNA knock down or
genetic deletion of PDPN also resulted in impaired DC migra-
tion in vivo and impeded motility along the FRC network in vitro.
Furthermore, the interaction between PDPNandCLEC-2was suf-
ﬁcient to induce protrusion formation in a 3D tissue engineered
model. Therefore, both CLEC-2 on DCs and PDPN on stromal
cells are necessary for migratory DCs to efﬁciently reach LNs and
initiate immune responses (Acton et al., 2012).
Podoplanin signaling has intrinsic effects on the prolifera-
tion, migration, and tube formation of LECs. Navarro et al.
(2008, 2010) demonstrated that knocking down PDPN expression
in vitro inhibited the ability of LECs to properly polarize toward
a wound and migrate to close the wound. Reduced PDPN levels
also decreased capillary formation when the cells were plated in
a deformable 3D matrix (Navarro et al., 2008). These effects were
mediated by decreased RhoA activity and increased Cdc42 activ-
ity in cells lacking PDPN (Navarro et al., 2010). The mechanism
underlying this effect was further investigated by Osada et al.
(2012), who found that when LECs were incubated with WT
but not CLEC-2−/− platelets, the migration, proliferation, and
in vitro tube formation of LECs was inhibited. This inhibition
was mediated at least in part by BMP9 released in granules
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from the platelets upon contact with the LECs (Osada et al.,
2012). In contrast, Bertozzi et al. (2010) found that co-culture
of platelets with LECs did not affect their viability or prolifera-
tion. Morework is necessary to determinewhether CLEC-2 signals
from platelets or other cells provide important signals to LECs
in vivo.
In addition to its high expression on stromal cells, several
recent reports have described PDPN expression on hematopoi-
etic cells, including subsets of T cells and macrophages (Hou
et al., 2010; Peters et al., 2011; Kerrigan et al., 2012). Interestingly,
in these cases, as in those from cancer studies, PDPN expres-
sion is usually correlated with inﬂammatory or disease settings.
In experimental autoimmune encephalomyelitis (EAE), ectopic
germinal centers form in the CNS and are believed to acceler-
ate inﬂammation and disease progression (Weyand et al., 2001).
TH17 cells are particularly important for the formation of these
ectopic germinal centers and EAE progression (Jäger et al., 2009).
PDPN expression has been reported in ectopic lymphoid tissues
in instances of chronic inﬂammation and cancer (Peduto et al.,
2009; Shields et al., 2010; Link et al., 2011), but only on FRC-
like stromal cells. Recently, Peters et al. (2011) found that TH17
cells generated in vitro and those found in inﬂamed CNS tissue
of mice with EAE express PDPN (Table 1). Administration of a
PDPN blocking antibody to mice with EAE did not attentuate
disease severity, but signiﬁcantly reduced the number of ectopic
germinal centers induced by TH17-mediated disease. While the
mechanism of PDPN function in T cells is not yet clear, it likely
plays an important role in regulating T cell physiology in inﬂamed
tissues.
Podoplanin expression has been observed on somemacrophage
subsets (Table 1). It was ﬁrst found on F4/80+ macrophages in
the red pulp of the spleen. These PDPN+ macrophages exhibited
markedphagocytic potential and elevatednumbers inmice follow-
ing systemic zymosan treatment (Hou et al., 2010). PDPN is also
expressed by inﬂammatory macrophages such as thioglycollate-
elicited peritoneal macrophages and LPS-treated RAW264.7 cells
(Kerrigan et al., 2012). These studies showed that expression of
PDPN by macrophages was sufﬁcient to induce CLEC-2-mediated
aggregation of platelets in vitro. While the in vivo functions of
PDPN expression by hematopoietic cells have not been fully eluci-
dated, interesting implications abound given what is known about
PDPN function in cancer and autoimmunity.
PDPN FUNCTIONS IN CANCER
The setting in which PDPN has been most extensively stud-
ied is cancer. Given that it is a speciﬁc marker of lymphatic
vessels, and that increased lymphangiogenesis is often corre-
lated with poor prognosis in cancer patients, the numbers of
PDPN+ vessels in a tumor is often used as a diagnostic marker
(Breiteneder-Geleff et al., 1997; Ji, 2006; Swartz and Lund, 2012).
Additionally, PDPN is upregulated on tumor cells themselves
in several cancer types, including squamous cell carcinoma of
the lung, head, and neck (Kato et al., 2005; Martín-Villar et al.,
2005; Schacht et al., 2005; Wicki et al., 2006), malignant mesothe-
lioma (Kimura and Kimura, 2005; Ordóñez, 2005), and brain
tumors (Mishima et al., 2006; Shibahara et al., 2006). PDPN is
often expressed at the leading invasive edge of tumors and appears
to play a role in EMT, invasion, and metastasis (Martín-Villar
et al., 2006; Wicki et al., 2006). Interactions between CLEC-2
and PDPN in tumors also likely play a role in tumor pro-
gression and metastasis due to platelets interacting with tumor
cells (Lowe et al., 2012). However, the exact mechanism of
PDPN action in tumor cells is still unclear; in some cases,
PDPN expression mediates the downregulation of E-cadherin
and promotes EMT (Martín-Villar et al., 2006), while in others,
PDPN expression enhances tumorigenesis and metastasis in the
absence of EMT (Wicki et al., 2006). In vitro studies have pro-
vided compelling evidence that forced expression of PDPN in
cells that normally lack this protein results in a more mesenchy-
mal phenotype, actin-rich ﬁlopodia, and increased migration
and invasion, as discussed above (Martín-Villar et al., 2005, 2006;
Wicki et al., 2006).
Interestingly, PDPN is also upregulated by cancer-associated
ﬁbroblasts (CAFs) in the stroma surrounding various tumors,
including adenocarcinomas and colorectal cancers (Kitano et al.,
2010). There is a wealth of data on the tumor-promoting effects
of CAFs, which has been reviewed elsewhere (Kalluri and Zeis-
berg, 2006; Gaggioli et al., 2007), but only recently have speciﬁc
functions for PDPN on CAFs been examined. Generally, the
expression of PDPN on CAFs is associated with poor progno-
sis: for example, one study found that invasive adenocarcinomas
in the lung had PDPN+ ﬁbroblasts, while non-invasive cases
were all negative for PDPN staining (Kawase et al., 2008). Fur-
ther studies from this group have examined the mechanism by
which PDPN enhances the tumor-promoting effects of CAFs.
They found that ﬁbroblasts isolated from the vascular adventitia
(VAFs) were better at promoting tumor growth than ﬁbrob-
lasts isolated from human lungs. One of the most differentially
expressed genes in these cells was PDPN,and knockdownof PDPN
in the VAFs abrogated their tumor-promoting effects (Hoshino
et al., 2011). Further studies indicated that this activity may be
due in part to increased RhoA activity in the PDPN+ ﬁbroblasts
(Ito et al., 2012).
While these studies illustrate that PDPN expression in CAFs
is linked to poor prognosis for patients, it is important to keep
in mind that the effect of PDPN+ CAFs likely depends on the
type of tumor cells and the tissue from which the CAFs orig-
inate. In fact, one study of colorectal CAFs found that PDPN
expressionwas correlatedwith a better prognosis (Yamanashi et al.,
2009). Knockdown of PDPN in CAFs resulted in enhanced cancer
cell migration in a transwell assay. Furthermore, PDPN expres-
sion was seen in stroma surrounding the tumors in many areas
except at the invasive front (Yamanashi et al., 2009). Thus, it was
postulated that PDPN expressing stroma could act as a physical
barrier to tumor cell invasion into surrounding tissues. In fact,
this theory has been presented elsewhere and for other mucins
(Zimmer et al., 1999). The negative charge of the many sialic acids
on these proteins acts to repel other molecules such as comple-
ment (Michalek et al., 1988; Meri and Pangburn, 1990) and can
affect cell adhesion (Taylor and Drickamer, 2007). Whether these
properties play a role in PDPN function has not been deﬁnitively
examined but it is an attractive hypothesis, given that PDPN is
expressed on the apical surface of many cells that have contact
with proteinase-rich ﬂuids (i.e., lymph).
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While it is clear that PDPN plays an important role in tumor
progression and metastasis, more mechanistic studies are needed
to fully elucidate the function of this molecule. Furthermore, a
genetic dissection of PDPN function in malignant cells versus
in the surrounding tumor stroma will signiﬁcantly advance our
understanding of this molecule in cancer.
CONCLUSION
Emerging studies of PDPN suggest that this molecule plays diverse
roles throughout the body. It is involved in the development of the
heart, lung, and lymphatic system as well as driving inﬂamma-
tory diseases and metastasis. The majority of mechanistic data
available on the cellular functions of PDPN come from studies
of cancer progression and metastasis. Overexpression of PDPN
in various cell lines results in increased motility and a mesenchy-
mal phenotype in vitro and increased metastasis in vivo. These
changes occur through the interaction of PDPN with ERM pro-
teins and subsequent modulation of the Rho proteins and actin
cytoskeleton. While these studies are indispensable to our under-
standing of how PDPN functions, it is also critical to examine
PDPN in physiological settings, which we have begun to do
only recently. Studies of PDPN on LECs and FRCs have indi-
cated that it plays a critical role in mediating interactions with
platelets and DCs; however these studies have largely focused on
the effects of CLEC-2 engagement of PDPN rather than down-
stream effects in the PDPN-expressing cell. Furthermore, recent
studies of PDPN expression by leukocytes have demonstrated that
PDPN expression has intrinsic effects on these cells as well as
tumor cells.
There are still many unknowns about PDPN biology that
remain to be answered, but there are three pressing questions in the
ﬁeld: (1) What signaling pathways does endogenously-expressed
PDPNemploy? It is possible that expressionof PDPN in leukocytes
leads to similar downstream changes as in tumor cells; however,
it is likely that PDPN interacts with different molecules and sig-
naling pathways in stromal cells and leukocytes than in malignant
cancer cells. (2) What are the effects of CLEC-2 engagement of
PDPN? This interaction has been almost exclusively studied with
respect to signaling downstream of CLEC-2. However, in nearly
every instance where PDPN is expressed, whether by FRCs or
cancer cells, there will be CLEC-2+ cells in the nearby environ-
ment, including DCs or platelets. Given that overexpression of
PDPN has striking intrinsic effects on various cells, it stands to
reason that there could be some effect on PDPN signaling when it
is bound by CLEC-2. (3) What are the consequences of deleting
PDPN from cells that endogenously express it? This question has
been partially answered by studies of the developing heart, lungs,
and lymphatic system, but research has been limited by the lack
of a conditional PDPN knockout mouse. Once this tool is gener-
ated,wewill be able tomore closely examine the effects of PDPN in
adult animals and in speciﬁc tissues or cells. These studies will pro-
vide critical insight into whether PDPN is necessary only during
embryonic development or into adulthood for proper develop-
ment and maintenance of organs. Furthermore, we can study how
the deletion of PDPN in macrophages or T cells affects disease
progression. A better understanding of these open questions will
lead to great insights in the diverse ﬁelds of development, cellular
interactions in the immune system, and cancer progression and
metastasis.
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